[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,258,421
  • Shares Outstanding, K 29,599
  • Annual Sales, $ 389,130 K
  • Annual Income, $ 204,830 K
  • EBIT $ 198 M
  • EBITDA $ 204 M
  • 60-Month Beta 0.53
  • Price/Sales 25.64
  • Price/Cash Flow 46.23
  • Price/Book 7.34

Options Overview Details

View History
  • Implied Volatility 39.35% (+1.34%)
  • Historical Volatility 52.35%
  • IV Percentile 19%
  • IV Rank 20.50%
  • IV High 59.65% on 10/31/25
  • IV Low 34.12% on 05/13/26
  • Expected Move (DTE 26) 25.93 (7.48%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 3,758
  • Volume Avg (30-Day) 430
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 9,046
  • Open Int (30-Day) 7,960
  • Expected Range 320.66 to 372.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $1.91
  • Number of Estimates 4
  • High Estimate $2.12
  • Low Estimate $1.74
  • Prior Year $2.66
  • Growth Rate Est. (year over year) -28.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
297.02 +16.69%
on 08/03/26
369.00 -6.08%
on 07/29/26
+7.52 (+2.22%)
since 07/21/26
3-Month
285.07 +21.58%
on 06/02/26
382.54 -9.40%
on 06/30/26
+42.35 (+13.92%)
since 05/21/26
52-Week
136.73 +153.48%
on 09/10/25
382.54 -9.40%
on 06/30/26
+200.88 (+137.87%)
since 08/21/25

Most Recent Stories

More News
Stocks Settle Sharply Higher as Middle East Tensions Ease

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.48%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +1.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.78%. September E-mini...

ALK : 40.41 (+0.57%)
GOOGL : 344.82 (+1.22%)
MPC : 360.72 (+0.70%)
CRCL : 87.98 (+5.16%)
TRI : 105.53 (-0.33%)
OXY : 61.30 (-0.36%)
TSLA : 362.86 (+5.14%)
GLW : 149.84 (-1.06%)
FANG : 210.72 (-0.14%)
FERG : 242.24 (+1.55%)
SPY : 765.72 (+0.41%)
GME : 18.21 (+0.94%)
Stocks Rally on Easing Geopolitical Risks and US Economic Strength

The S&P 500 Index ($SPX ) (SPY ) today is up +1.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.081%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.40%. September E-mini S&P futures...

ALK : 40.41 (+0.57%)
GOOGL : 344.82 (+1.22%)
UAL : 113.17 (+1.31%)
ATKR : 93.60 (+0.12%)
DDOG : 235.62 (+1.32%)
SUPN : 45.85 (-3.37%)
CRCL : 87.98 (+5.16%)
$IUXX : 29,308.86 (+0.33%)
FICO : 1,172.67 (+1.99%)
ZNU26 : 108-135 (+0.14%)
MSFT : 483.24 (+0.43%)
TSLA : 362.86 (+5.14%)
Stocks Supported by Easing Middle East Tensions

The S&P 500 Index ($SPX ) (SPY ) today is up +0.84%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.47%. September E-mini S&P futures...

ALK : 40.41 (+0.57%)
ADI : 373.09 (+0.77%)
CRCL : 87.98 (+5.16%)
SLB : 53.87 (+0.60%)
OXY : 61.30 (-0.36%)
FANG : 210.72 (-0.14%)
FERG : 242.24 (+1.55%)
STX : 850.00 (-0.03%)
WDC : 459.44 (-2.05%)
AMD : 473.25 (+0.81%)
SPY : 765.72 (+0.41%)
GME : 18.21 (+0.94%)
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance...

KRYS : 346.58 (+2.84%)
Can Krystal Biotech's Gene Therapy Pipeline Finally Justify the Premium Beyond VYJUVEK?

Barchart Research What to Expect from KRYS Earnings KRYS Generated July 31, 2026 Current Price $341.12 EPS Estimate $$1.70 Consensus Rating Strong Buy Average Move 7.71% Can Krystal Biotech's Gene Therapy...

KRYS : 346.58 (+2.84%)
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August...

KRYS : 346.58 (+2.84%)
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

NEW YORK , July 20, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: 

KRYS : 346.58 (+2.84%)
TMHC : 72.45 (-0.03%)
AVNS : 24.99 (+0.04%)
BRK.A : 743,500.00 (-0.15%)
TPC : 91.27 (+1.01%)
BRK.B : 495.82 (-0.21%)
SPGI : 431.29 (-0.20%)
VVX : 78.50 (-0.65%)
3 Biotech Firms With Major Potential Catalysts in the Coming Months

The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms.

KRYS : 346.58 (+2.84%)
VERA : 32.28 (+3.25%)
ADMA : 9.84 (+0.82%)
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan  VYJUVEK is the first genetic...

KRYS : 346.58 (+2.84%)
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference...

KRYS : 346.58 (+2.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 363.48
2nd Resistance Point 355.75
1st Resistance Point 351.17
Last Price 346.58
1st Support Level 338.86
2nd Support Level 331.13
3rd Support Level 326.55

See More

52-Week High 382.54
Last Price 346.58
Fibonacci 61.8% 288.64
Fibonacci 50% 259.63
Fibonacci 38.2% 230.63
52-Week Low 136.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.